GILD Gilead spent almost a decade going nowhere. The June 2015 peak near 123 capped every rally attempt for nine straight years, while price ground sideways between the mid-50s and the low-90s. On a monthly chart that is not a range — that is a base, and one of the longest and cleanest ones on the large-cap biotech board.That base is now resolved. Price has cleared the 2015 high, backfilled into it, and is holding above it. The old ceiling has flipped into the floor, which is exactly the behaviour you want to see after a multi-year breakout.
Fundamental backdrop (context, not the thesis)
Gilead's HIV franchise remains the engine — Biktarvy plus the long-acting prevention pipeline gives the company an unusually visible revenue runway for a biotech, while oncology and cell therapy remain the optionality. A durable cash-generative core is the kind of fundamental that lets a decade-long base actually resolve upward instead of failing. Verify the latest earnings, guidance, and pipeline readouts yourself before acting on any of this — fundamentals move faster than chart structure.
Invalidation
The idea is wrong if we get a decisive monthly close back below ~115, which would put price back inside the old range and turn the breakout into a failed one. A weekly loss of the 123 shelf is the early warning; a monthly close below 115 is the exit. I'd rather be stopped out at a defined level than defend a broken structure.
Risks worth naming
Extended targets rest on a projection template, not on confirmed price action. Treat them as scenarios.
Biotech carries binary event risk — trial results, regulatory decisions, patent cliffs — that no chart can price in advance.
Broad-market drawdowns will drag high-momentum names hardest, regardless of individual structure.
Position size for the timeframe. A monthly-chart idea needs a monthly-chart stop, which means wider risk per unit than most traders are used to.
Trade ativo
Inverse head and shoulders on daily.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.